RxDoctor Payments Data

Claudio Palma, MD

Pain Medicine · San Francisco, CANPI 1154348464

Payments from drug & device makers

$2,652in general payments, 2019–2025

Across 132 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$626
  • Indivior Inc.$273
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$226
  • Pfizer$192
  • Curonix LLC$188
  • Abbott$160
  • plus $988 from 15 others

What the payments were for

  • Food & beverage$2,61098%
  • Education$422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,652 in reported general payments places this provider in the 55th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$56,324
Medicare patients
74
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl41$35,965
BelbucaBuprenorphine Hcl35$14,027
Xtampza ErOxycodone Myristate12$13,216
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl40$8,694
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen138$5,147
Lidocaine26$3,132
Fentanyl21$1,882
Acetaminophen-CodeineAcetaminophen With Codeine84$1,692
Tizanidine Hcl22$1,395
Morphine Sulfate ErMorphine Sulfate75$1,304
Pregabalin49$1,212
Oxycodone Hcl89$1,084
Gabapentin88$941
Morphine Sulfate16$697
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$626$27,24247 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate$76$9,39156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 pain medicine providers in California.

Other pain medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →